Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.20.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Total revenue $ 22,270 $ 13,285
Operating expenses:    
Research and development 50,519 30,202
General and administrative 20,077 14,082
Loss on impairment of in-process research and development 22,123 0
Total operating expenses 92,719 44,284
Loss from operations 70,449 30,999
Interest and other income, net 2,323 751
Interest and other expense, net (1,298) (990)
Change in fair value of warrant liabilities 3 951
Net loss attributable to common shareholders $ 69,421 $ 30,287
Net loss per share attributable to common shareholders:    
Basic and diluted $ 1.86 $ 1.02
Weighted average number of shares used in net loss per share calculations:    
Basic and diluted 37,770,378 29,601,692
Net loss attributable to common shareholders $ 69,421 $ 30,287
Other comprehensive loss:    
Unrealized gain (loss) on available-for-sale securities 18 0
Comprehensive loss 69,403 30,287
Research And Development Revenue | Other    
Total revenue 0 196
Research And Development Revenue | Related Party    
Total revenue 19,499 7,087
Grant    
Total revenue $ 2,771 $ 6,002